



GMMM Interface Prescribing
Subgroup



Agenda

9th July 2015, 1pm-3pm

HMR CCG

Room G10, Number One Riverside, Smith St. Rochdale OL16 1XU

[Declarations of Interest](#) (new declarations only)

Apologies:

	ENC
1) Draft Minutes of 11th June 2015	Item 1
2) Matters Arising <ul style="list-style-type: none"> a) RAG List Recommendations from March meeting (Drugs for alcohol dependence, Chapter 3 and 13) – now GMMM approved b) RAG List Recommendations from April meeting (Chapter 1 & 8) – awaiting GMMM approval c) RAG List Recommendations from May meeting – comments received d) RAG List Recommendations from June meeting – currently out for comment until 6th August 2015. e) Review of Antipsychotics in BPSD – comments received f) Inclusion of Grey/DNP List drugs on RAG list g) Amiodarone in paediatrics RAG status 	Item 2c Item 2e(i) Item 2e(ii) Item 2e(iii)
3) Interface processes for consultation on RAG list and Shared Care Protocols	Item 3a Item 3b Item 3c Item 3d
4) Apraclonidine eye drops	Item 4
5) NICE's guideline on Challenging behaviour and learning disabilities - implications regarding medication & RAG status	
6) Drugs requiring a review of RAG status <ul style="list-style-type: none"> • Amantadine for MS • Ezetimibe • Pregabalin in neuropathic pain • Acetazolamide for idiopathic intracranial hypertension 	
7) New Drugs from NTS and Formulary Subgroup Requiring a RAG Status <ul style="list-style-type: none"> • Simbrinza® (Brinzolamide/Brimonidine) eye drops • Secukinumab for moderate to severe plaque psoriasis – suggest RED. • Apremilast for moderate to severe chronic plaque psoriasis and active 	

psoriatic arthritis – suggest RED.	
8) Share Care Protocols for approval <ul style="list-style-type: none"> • Mercaptopurine and Azathioprine for Inflammatory bowel disease • Azathioprine for the treatment of chronic inflammatory bowel disease (unlicensed use) in paediatric patients • SSRIs in children and adolescents for OCD & BDD • SSRIs in children and adolescents for depression • SSRIs in children and adolescents for anxiety • Antipsychotics for schizophrenia in children & adolescents • Antipsychotics for OCD in children & adolescents • Antipsychotics for Bipolar in children & adolescents • Ethinylestradiol for pubertal induction – to follow • Ciclosporin for paediatric nephrotic syndrome – to follow 	Item 8a Item 8b Item 8c Item 8d Item 8e Item 8f Item 8g Item 8h
9) Nalmefene SCP – 2nd draft	Item 9
10) Clarification of 6mg dose of melatonin in melatonin SCP	Item 10
11) Updates from other groups	
a) Formulary Subgroup (verbal)	
b) New Therapies Subgroup (verbal)	
c) GMMMGMG (verbal)	
12) AOB <ul style="list-style-type: none"> • Cancer Supportive Care Tariff • Christie & general non-compliance with principles of RAG 	
Date of Next Meeting: 13th August 2015, 1pm-3pm Room G10, HMR CCG, Number One Riverside, Smith St, Rochdale OL16 1XU	